Valence Labs (RXRX)

Executive Summary

Valence Labs, the AI research engine of Recursion (ticker: RXRX), is pioneering the development of 'virtual cells'—AI models that predict, explain, and decode cellular biology. Founded in 2023 and headquartered in Montreal, the company leverages Recursion's vast biological datasets, automated laboratories, and supercomputing infrastructure to accelerate therapeutic discovery. By modeling cellular behavior computationally, Valence aims to reduce the time and cost of drug development, offering a platform that can systematically explore biology at an unprecedented scale. As a private entity with an estimated valuation of ~$1.85B, Valence serves as the core AI innovation hub within Recursion, driving the company's mission to industrialize drug discovery. Valence Labs is positioned at the intersection of artificial intelligence and biotechnology, capitalizing on Recursion's decade-long investment in phenotypic data and high-throughput screening. Its primary goal is to create foundational AI models that can simulate cellular responses to perturbations, enabling researchers to identify novel targets and candidate compounds more efficiently. While still in early stages, the company's integration with Recursion's pipeline provides a clear path to validation and commercialization. Near-term catalysts include technical milestones such as the release of advanced virtual cell models, strategic partnerships with pharmaceutical companies, and updates on how Valence's AI is being deployed within Recursion's own drug programs. Success in these areas could significantly enhance the platform's credibility and drive adoption across the industry.

Upcoming Catalysts (preview)

• Q3 2026Publication or release of an advanced virtual cell model demonstrating predictive accuracy in disease-relevant assays70% success
• Q4 2026Announcement of a major pharmaceutical partnership to apply Valence's AI platform in drug discovery60% success
• Q2 2026Update from Recursion on the use of Valence's AI models to advance its clinical-stage pipeline80% success